Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytoMed Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage cell therapy company. Form 6-K reports furnish clinical and regulatory updates for CAR γδ T cell, iPSC-derived γδ NKT cell, γδ T cell, and cord blood-derived Natural Killer cell programs, along with annual financial results and research expense disclosures.
The filing record also covers annual general meeting materials, proxy voting items, subsidiary structure changes, completed technology and asset acquisitions, non-dilutive subsidiary financing, and shareholder communication matters. These documents frame CytoMed's governance, capital resources, development spending, and corporate organization across Singapore and Malaysia.
CytoMed Therapeutics Limited reported the results of its Annual General Meeting of Shareholders held on May 22, 2026 in Singapore. Holders of 7,162,501 ordinary shares, representing about 60.01% of issued and outstanding shares as of May 19, 2026, were represented, establishing a quorum.
All ten proposals were approved as recommended by the Board. Shareholders adopted the directors’ statement and audited financial statements for the year ended December 31, 2025, and re-elected Dr. Yew Chak Hua and Dr. Toh Keng Kiat as directors.
They approved a waiver related to the Singapore Code on Take-overs and Mergers, ratified WWC, P.C. and KE Trust PAC as independent auditors for 2026, approved directors’ fees of US$70,000 for 2026, and authorized the directors to issue ordinary shares until the next annual general meeting or the date it is required by law to be held, whichever is earlier.
CytoMed Therapeutics Ltd director Toh Keng Kiat has reported initial share ownership in the company. The filing shows direct beneficial ownership of 4,000 Ordinary Shares with no par value per share. This is a routine disclosure of existing holdings and does not reflect a new purchase or sale.
CytoMed Therapeutics Ltd director Yew Chak Hua reported initial ownership of 2,469 Ordinary Shares, no par value per share. This Form 3 establishes his status as a director and shows a relatively small direct stake. The report does not indicate any recent purchases, sales, or option exercises, only current holdings.
CytoMed Therapeutics Ltd director Leong Mark Kei Wei filed an initial Form 3 to report beneficial ownership as an insider of the company. The available data for this filing shows no reported transactions in the issuer’s securities, indicating this is a baseline ownership disclosure rather than a trade report.
CytoMed Therapeutics Ltd director and more-than-10% owner Choo Chee Kong filed an initial Form 3 reporting his ownership in the company. The filing shows beneficial ownership of 2,075,310 Ordinary Shares held through Glorious Finance Limited, 194,112 Ordinary Shares held through EP Capital Inc., and 318,324 Ordinary Shares held directly by Mr. Choo. He disclaims beneficial ownership of 1,697,981 Ordinary Shares held by Glorious Finance to the extent he has no economic interest in those shares.
CytoMed Therapeutics Ltd executive Tan Yoong Ying, the Chief Corporate Officer, reported his initial ownership on a Form 3. He holds 25,781 Ordinary Shares with no par value per share, held directly. The filing does not show any recent purchases or sales, only his existing stake.
CytoMed Therapeutics Ltd filed an initial insider ownership report for its Chief Financial Officer, Yvonne Goh. The filing shows she directly holds 25,781 Ordinary Shares of the company. This Form 3 does not report any new share purchases, sales, or option exercises, only her existing stake.
CytoMed Therapeutics Limited reported that its Chairman and Director, Mr. Choo Chee Kong, entered into a binding private share purchase agreement on May 13, 2026 to acquire 112,000 ordinary shares of the company from an independent arm's-length shareholder for cash consideration.
The transaction was a privately negotiated deal between Mr. Choo and the shareholder. The company was not a party to the transaction and did not receive any proceeds. Mr. Choo intends to negotiate privately with additional independent arm's-length shareholders to further increase his shareholding.
CytoMed Therapeutics Limited reports that its wholly owned subsidiary Advance Cancer Centre Pte. Ltd., established in 2020, has been renamed CytoMed International Pte. Ltd., effective May 6, 2026. The new name is meant to reflect a stronger push into international markets.
The company plans to expand its footprint through overseas joint ventures, international medical tourism initiatives, and appointment of overseas representatives, with an initial focus on Asia, especially China, where its allogeneic gamma delta T cell technology is drawing partner interest following China’s Directive 818. The subsidiary currently holds a 19.0% equity interest in a licensed clinic in Malaysia and may increase this stake in the future. The name change does not alter the subsidiary’s legal entity, ownership structure, or contracts, and CytoMed intends to use internal resources to fund this international platform.